About: Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model
Creator	Li, H Ng, K Peiris, J Nicholls, John Chan, Michael Cheung, M Hui, P Ng, Mandy Kuok, Denise
Source	Elsevier; Medline; PMC
abstract	Abstract Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has emerged as a coronavirus infection of humans in the past 5 years. Though confined to certain geographical regions of the world, infection has been associated with a case fatality rate of 35%, and this mortality may be higher in ventilated patients. As there are few readily available animal models that accurately mimic human disease, it has been a challenge to ethically determine what optimum treatment strategies can be used for this disease. We used in-vitro and human ex-vivo explant cultures to investigate the effect of two immunomodulatory agents, interferon alpha and cyclosporine, singly and in combination, on MERS-CoV replication. In both culture systems the combined treatment was more effective than either agent used alone in reducing MERS-CoV replication. PCR SuperArray analysis showed that the reduction of virus replication was associated with a greater induction of interferon stimulated genes. As these therapeutic agents are already licensed for clinical use, it may be relevant to investigate their use for therapy of human MERS-CoV infection.
has issue date	2018-07-31(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2018.05.007
bibo:pmid	29772254
has license	els-covid
sha1sum (hex)	9737d02107d89785da706f34c49fe4d38186487c
schema:url	https://doi.org/10.1016/j.antiviral.2018.05.007
resource representing a document's title	Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model
has PubMed Central identifier	PMC7113667
has PubMed identifier	29772254
schema:publication	Antiviral Research
resource representing a document's body	covid:9737d02107d89785da706f34c49fe4d38186487c#body_text
is schema:about of	named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'combination' named entity 'COMBINATION' named entity 'EFFECT' named entity 'IN-VITRO' named entity 'REPLICATION' named entity 'MODEL' named entity 'CULTURE' named entity 'INTERFERON ALPHA' named entity 'CYCLOSPORINE' named entity 'TREATMENT' named entity 'HUMAN' named entity 'VIVO' named entity 'MERS' named entity 'culture' named entity 'IFN' named entity 'antiviral therapies' named entity 'IFN' named entity 'type I IFN' named entity 'virus' named entity 'Rotterdam' named entity 'ThermoFisher' named entity 'antibody' named entity 'virus' named entity 'CsA' named entity 'nucleocapsid protein' named entity 'HCoV-EMC' named entity 'signaling cascades' named entity 'phosphorylation' named entity 'MERS-CoV' named entity 'zoonotic' named entity 'cyclosporine' named entity 'Kadmon pharmaceuticals' named entity 'innate immune' named entity 'interferon' named entity 'cyclosporine' named entity 'MERS-CoV' named entity 'IFN' named entity 'lung' named entity 'CsA' named entity 'Netherlands' named entity 'protein' named entity 'IFN' named entity 'HCoV-EMC' named entity 'PI3K/Akt/mTOR' named entity 'Qiagen' named entity 'ribavirin' named entity 'human lung' named entity 'coronavirus infections' named entity 'transcriptional activation' named entity 'STAT1' named entity 'Erasmus MC' named entity 'CsA' named entity 'STAT1' named entity 'CsA' named entity 'Minimum Essential medium' named entity 'mTOR' named entity 'interferon' named entity 'long-term' named entity 'infection' named entity 'Dynabeads' named entity 'IFN' named entity 'IFNAR1' named entity 'phosphorylation' named entity 'treatment options' named entity 'MERS-CoV' named entity 'IFN' named entity 'infection' named entity 'histogram' named entity 'hypoxanthine phosphoribosyltransferase' named entity 'MERS-CoV' named entity 'endothelial cell' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software